Page last updated: 2024-11-02

pioglitazone and Minimal Disease, Residual

pioglitazone has been researched along with Minimal Disease, Residual in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brower, V1

Other Studies

1 other study available for pioglitazone and Minimal Disease, Residual

ArticleYear
Pioglitazone with imatinib in CML may reduce residual disease.
    The Lancet. Oncology, 2017, Volume: 18, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress

2017